


# PRODUCT INFORMATION



## SR 3306

Item No. 45342

**CAS Registry No.:** 1128096-91-2  
**Formal Name:** N-[4-[3-(6-methyl-3-pyridinyl)-1H-1,2,4-triazol-1-yl]phenyl]-4-[3-(4-morpholinyl)phenyl]-2-pyrimidinamine  
**MF:** C<sub>28</sub>H<sub>26</sub>N<sub>8</sub>O  
**FW:** 490.6  
**Purity:** ≥98%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

SR 3306 is supplied as a solid. A stock solution may be made by dissolving the SR 3306 in the solvent of choice, which should be purged with an inert gas. SR 3306 is slightly soluble (0.1-1 mg/ml) in DMSO.

### Description

SR 3306 is a pan-JNK inhibitor (IC<sub>50</sub>s = 67, 283, and 159 nM for JNK1, JNK2, and JNK3, respectively).<sup>1</sup> It is selective for JNK1-3 over p38 MAPK (IC<sub>50</sub> = >20 μM). SR 3306 (300-1,000 nM) reduces cell death induced by N-methyl-4-phenylpyridinium (MPP<sup>+</sup>) in primary rat mesencephalic dopaminergic neurons. It reduces MPTP- or 6-OHDA-induced neurodegeneration of dopaminergic neurons in the mouse substantia nigra pars compacta.<sup>1,2</sup> SR 3306 (10 mg/kg) decreases D-amphetamine-induced circling in rats in a 6-OHDA model of Parkinson's disease.<sup>2</sup> It also enhances leptin-induced STAT3 activation in the hypothalamus, reduces food intake, decreases body weight in diet-induced obese (DIO) mice when administered at a dose of 30 mg/kg.<sup>3</sup>

### References

1. Chambers, J.W., Pachori, A., Howard, S., *et al.* Small molecule c-jun-N-terminal kinase (JNK) inhibitors protect dopaminergic neurons in a model of Parkinson's disease. *ACS Chem. Neurosci.* **2(4)**, 198-206 (2011).
2. Crocker, C.E., Khan, S., Cameron, M.D., *et al.* JNK Inhibition protects dopamine neurons and provides behavioral improvement in a rat 6-hydroxydopamine model of Parkinson's disease. *ACS Chem. Neurosci.* **2(4)**, 207-212 (2011).
3. Gao, S., Howard, S., and LoGrasso, P.V. Pharmacological inhibition of c-Jun N-terminal kinase reduces food intake and sensitizes leptin's anorectic signaling actions. *Sci. Rep.* **7**, 41795 (2017).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/13/2026

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM